Daniel E. Singer, MD; Paul D. Ziegler, MS; Jodi L. Koehler, MS; et al.
free access
JAMA Cardiol. 2021;6(12):1364-1369. doi:10.1001/jamacardio.2021.3702
This case-crossover study evaluates the temporal association between episodes of atrial fibrillation and stroke in patients with cardiac implantable electronic devices.
Zachary T. Yoneda, MD, MSCI; Katherine C. Anderson, MS, CSG; Joseph A. Quintana, MD; et al.
open access
has active quiz
JAMA Cardiol. 2021;6(12):1371-1379. doi:10.1001/jamacardio.2021.3370
This cohort study of individuals with early-onset atrial fibrillation examines the prevalence of disease-associated variants in susceptibility genes for inherited cardiomyopathy and arrhythmia syndromes.
Mario Gaudino, MD, PhD; Katia Audisio, MD; Mohamed Rahouma, MD; et al.
free access
has audio
JAMA Cardiol. 2021;6(12):1380-1386. doi:10.1001/jamacardio.2021.3866
This post hoc analysis of the Arterial Revascularization Trial compares the long-term clinical outcomes of skeletonized and pedicled internal thoracic artery harvesting for coronary artery bypass surgery.
-
Podcast:
Long-term Clinical Outcomes of Skeletonized vs Pedicled Internal Thoracic Artery Harvesting in the ART Trial
-
Editorial
Coronary Artery Bypass Grafting With the Internal Thoracic Artery: A Great Operation With Some Unanswered Questions
Frank W. Sellke, MD
JAMA Cardiol
-
Podcast:
Long-term Clinical Outcomes of Skeletonized vs Pedicled Internal Thoracic Artery Harvesting in the ART Trial
Mitesh S. Patel, MD, MBA; Chethan Bachireddy, MD, MS; Dylan S. Small, PhD; et al.
free access
JAMA Cardiol. 2021;6(12):1387-1396. doi:10.1001/jamacardio.2021.3176
This randomized clinical trial examines the use of differing methods of goal setting and implementation in gamification of individuals at risk for major cardiovascular events.
Jarett D. Berry, MD; Vijay Nambi, MD, PhD; Walter T. Ambrosius, PhD; et al.
free access
JAMA Cardiol. 2021;6(12):1397-1405. doi:10.1001/jamacardio.2021.3187
This post hoc analysis of SPRINT examines whether elevated high-sensitivity cardiac troponin T and N-terminal pro鈥揃-type natriuretic peptide levels can identify individuals with the greatest risk for mortality and heart failure and the largest benefit from intensive systolic blood pressure lowering.
Yiyi Zhang, PhD; Mark J. Pletcher, MD, MPH; Eric Vittinghoff, PhD; et al.
free access
JAMA Cardiol. 2021;6(12):1406-1413. doi:10.1001/jamacardio.2021.3508
This cohort study evaluates the association between low-density lipoprotein cholesterol and development of cardiovascular disease later in life.
-
Editor's Note
Transforming the Paradigm for Lipid Lowering
Ann Marie Navar, MD, PhD; Gregg C. Fonarow, MD
JAMA Cardiol
Muthiah Vaduganathan, MD, MPH; Brian L. Claggett, PhD; Stephen J. Greene, MD; et al.
free access
JAMA Cardiol. 2021;6(12):1415-1423. doi:10.1001/jamacardio.2021.3651
This decision analytical model study quantifies newly eligible treatment candidates for sacubitril/valsartan under the expanded US Food and Drug Administration labeling and uses data from the PARAGON-HF trial to evaluate treatment effects and the number needed to treat to prevent 1 worsening HF event.
Augustin Coisne, MD, PhD; David Montaigne, MD, PhD; Samy Aghezzaf, MD; et al.
free access
JAMA Cardiol. 2021;6(12):1424-1431. doi:10.1001/jamacardio.2021.3718
This cohort study assesses the natural history of outpatients with native aortic stenosis based on a large regionwide population study with inclusion by all cardiologists regardless of their mode of practice.
Inbar Raber, MD; Mahmoud Al Rifai, MD, MPH; Cian P. McCarthy, MB, BCh, BAO; et al.
free access
JAMA Cardiol. 2021;6(12):1432-1439. doi:10.1001/jamacardio.2021.3385
This cross-sectional study determines whether gender differences exist in the reimbursements, charges, and reimbursement per charge from the Centers for Medicare & Medicaid Services.